“…); (2) Understanding the advantages and limitations of different molecular platforms for clinical translation, establish new chemistry for probe synthesis and preparation, keep testing novel strategies for design new generation of probes, incorporate signal amplification, and targeted imaging mechanisms into the probe, develop generalizable approach for facilitating probe translation, and combine imaging and therapy together; (3) Exploring the potential use of multimodality imaging, examine the necessity of combining different imaging modalities for different medical scenarios, supply well-designed and rationalized multimodality imaging probes to the research community; (4) Realize multiplex imaging ability through novel imaging modalities and probes, integrate in vitro diagnosis and pathology and in vivo molecular imaging to achieve best diagnosis and management of diseases; (5) Develop new imaging modalities or hybrid imaging modalities as mentioned above. Besides the conventional imaging modalities (MRI, CT, PET, SPECT, optical imaging), novel single or hybrid imaging modalities such as Raman imaging, Cerenkov luminescence imaging, X-ray excited luminescence imaging, or X-ray excited acoustic imaging could surpass many traditional imaging modalities and provide new information on diseases and complex mechanisms (Keren et al, 2008;Sun et al, 2011;Xu et al, 2011;Xiang et al, 2013).…”